| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
|
Still deciding? Get samples of US$ 60/g
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Product Name | Acalabrutinib |
| Appearance | White powder |
| Purity | 98% |
| CAS | 859-18-7 |
ACP-196 is an experimental anticancer drug and a selective Bruton tyrosine kinase (BTK) inhibitor. This kinase transmits signals from the B cell receptor (BCR), so any inherited BTK mutation can lead to B cell immune deficiency. Therefore, BTK inhibitors targeting B cell signaling have shown great promise in the treatment of chronic lymphocytic leukemia (CLL). AcChemicalbookalabrutinib is an experimental anticancer drug and a selective inhibitor of Bruton tyrosine kinase (BTK). This kinase transmits signals from the b cell receptor (BCR), so any BTK gene mutation can lead to b cell immune deficiency. Therefore, BTK inhibitors targeting b-cell signal transduction have shown great potential in the treatment of chronic lymphocytic leukemia (CLL).
){kind=link}